Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Moderna

Tracked across 53 events · 3900 articles · First seen Mar 09, 2018 · Last active Sep 23, 2026

Sentiment
23
Attention
8
Events
53
Relationships
176
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
7 75
Regulatory
Impact: Moderna is the developer of the mFlusiva mRNA flu vaccine, which is currently under review for approval by the United States — Food and Drug Administration. The positive recommendation from the advisory panel is a significant step towards market entry, potentially boosting its stock and market position in the vaccine sector.
Jun 18, 2026 · 28 articles
6 75
Tech
Impact: Moderna is the clinical-stage biotechnology company developing the gene therapy SRD-002 for heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The positive DMC recommendation for its MUSIC-HFpEF trial and the ongoing MUSIC-HFrEF trial are significant milestones for the company, supporting its continued advancement in cardiovascular gene therapy.
Jun 25, 2026 · 6 articles
2 10
Business
Impact: Moderna appointed Michael Francis Crotty to its board, gaining financial expertise as it prepares for product launches.
Jul 08, 2026 · 6 articles
3 30
Business
Impact: Moderna secured a major supply contract with the International — European Commission for its RSV vaccine, enhancing its commercial prospects and competitive position against GSK and Pfizer.
Jul 09, 2026 · 6 articles
7 80
Regulatory
Impact: Moderna received its fourth FDA-approved product and first mRNA flu vaccine, boosting its commercial prospects and validating its mRNA platform.
Aug 05, 2026 · 105 articles
4 70
Regulatory
Impact: Moderna received FDA approval for its updated COVID-19 vaccines, strengthening its competitive position and revenue outlook for the 2026-2027 season.
Aug 27, 2026 · 6 articles
7 95
Tech
On August 19, 2026, Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's immunotherapy Pembrolizumab, met its primary and secondary endpoints in a Phase 3 trial involving 1,137 patients…
Impact: Moderna is the co-developer of the vaccine and the primary beneficiary, with its stock more than doubling and market cap surging by nearly $40 billion. The trial success validates its mRNA platform and could lead to its entry into the cancer drug market, helping offset declining COVID-19 vaccine sales.
Aug 19, 2026 · 126 articles
2 20
Tech
Moderna announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology Congress 2026, to be held October 23-27 in Madrid,…
Impact: Moderna is the central actor, announcing the ESMO abstract acceptances and hosting an investor webcast; positive Phase 3 melanoma data could materially support its oncology pipeline narrative and stock.
Sep 21, 2026 · 6 articles
6 85
Tech
Impact: Moderna>>> developed the mRNA-4194 vaccine using its mRNA technology, marking its first venture into cancer prevention, which could significantly expand its market and revenue streams.
Jun 08, 2026 · 6 articles
6 70
Tech
Impact: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.
May 22, 2026 · 36 articles
6 70
Tech
Impact: As the manufacturer of intismeran, Moderna>>> is a key beneficiary of the positive clinical trial results, which could lead to increased revenue and market share in cancer treatment. The success of intismeran validates Moderna>>>'s mRNA vaccine platform for oncology applications.
Jun 01, 2026 · 6 articles
2 30
Domestic
Impact: Received FDA approval for its mRNA flu vaccine mFlusiva, which showed 27% higher efficacy; expects doses in pharmacies soon, potentially boosting revenue.
Sep 02, 2026 · 20 articles
4 75
Tech
Impact: Moderna's mRNA technology is being applied to a Lynch syndrome vaccine, potentially opening a new market and reinforcing its position in mRNA therapeutics.
Aug 06, 2026 · 20 articles
4 75
Regulatory
Impact: Moderna, a key player in mRNA vaccines, is likely to see increased investor confidence and market opportunities following the FDA's approval of an mRNA flu vaccine.
Aug 06, 2026 · 6 articles
7 60
International
Impact: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.
May 21, 2026 · 627 articles
8 20
Accidents
Impact: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
7 70
Accidents
Impact: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.
Aug 01, 2026 · 301 articles
8 20
Accidents
Impact: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.
May 18, 2026 · 505 articles
8 25
Accidents
Impact: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.
Mar 09, 2018 · 543 articles
4 -60
Business
Impact: Moderna fell 23.5% after surging 177% the previous day, making it the biggest decliner in healthcare.
Aug 20, 2026 · 15 articles
7 60
Domestic
Impact: Soared 150% on positive cancer vaccine data, a major gain.
Aug 19, 2026 · 133 articles
2 10
Tech
Researchers from the University of Geneva and Geneva University Hospitals published a study in Science Translational Medicine identifying why some people experience stronger side effects after mRNA COVID-19 vaccination. The team monitored 51 healthy individuals…
Impact: Partially funded the research on its mRNA vaccine platform; findings could support development of better-tolerated mRNA vaccines, a modest positive for its long-term product pipeline.
Sep 17, 2026 · 6 articles
4 50
Business
Impact: Moderna is an immigrant-founded unicorn company that has gone public since 2016.
Jun 04, 2026 · 6 articles
4 -5
Regulatory
Impact: Moderna is another pharmaceutical company that entered into advance purchase agreements with the International — European Commission, also mentioned in the context of the secret vaccine deals.
Jun 11, 2026 · 7 articles
4 10
Accidents
Impact: Moderna is one of the groups receiving funding to develop an Ebola vaccine, indicating potential future market opportunities.
Jun 04, 2026 · 12 articles
2 20
Business
Impact: Moderna>>> is a participating supplier in the Asian Safety and Security Online Exhibition 2026>>> (ASSOE 2026), gaining international exposure and sourcing opportunities.
Jun 01, 2026 · 7 articles
4 20
Business
Impact: Moderna's co-founder, Robert Langer, spoke at NextRise 2026 on bio innovation, indirectly associating Moderna with the event's focus on cutting-edge technologies.
Jun 26, 2026 · 8 articles
4 -5
Domestic
Impact: One of the vaccine manufacturers; similar to Pfizer, minimal direct impact.
Aug 06, 2026 · 17 articles
2 -10
Domestic
Forbes reported on Sept. 20 that Vivek Ramaswamy, the Republican nominee for governor of United States — Ohio, is now worth an estimated $2.3 billion, up from $1.8 billion a year earlier and about $1…
Impact: Moderna reached a multi-billion-dollar patent litigation settlement with Roivant in March, including a $950 million payment and up to $1.3 billion contingent on appeal. The settlement strengthened Roivant's balance sheet at Moderna's expense.
Sep 20, 2026 · 6 articles
4 10
Domestic
Impact: Moderna is named as a donor to Vaccinate Your Family, indicating its financial support for pro-vaccine advocacy, which indirectly benefits its vaccine business.
May 18, 2026 · 7 articles
+ 23 more events View on Dashboard
100 Moderna reported positive trial resultsModerna Merck mRNA...
95 Moderna announced trial resultsModerna Merck mRNA...
84 Moderna developed vaccineModerna Merck mRNA...
73 Moderna surged in tradingModerna Merck mRNA...
65 Moderna plan to seek approvalModerna Merck mRNA...
60 Moderna faced political headwindsModerna Merck mRNA...
60 Moderna faced political headwinds Donald TrumpModerna Merck mRNA...
60 JPMorgan Chase said launch key to profitability ModernaModerna Merck mRNA...
60 Morgan & Morgan said launch key to profitability ModernaModerna Merck mRNA...
50 Merck & Co. jointly developed therapy ModernaModerna intismeran...
40 Moderna announced investor webcastModerna intismeran...
ERGEN INTELLIGENCE
Track Moderna live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.